The Collaboration
As a large-cap ($51.9B) biopharma developing innovative therapeutics for diverse chronic diseases affecting different organ systems, Takeda Pharmaceuticals (OTCPK:TKPHF) (TAK) was expected to jump on the NASH bandwagon. In Q4/2017, Takeda initiated the first stage of NASH therapeutics development by signing an exclusive partnership agreement with privately-held HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis. Takeda's comment on the deal:
The ability to study pathophysiology in a human multi-cell system is crucial for our understanding of disease and how to develop best-in-class therapies,"